This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Boklan, J. Articles by Moore, M. A. S. Search for Related Content PubMed PubMed Citation Articles by Boklan, J. Articles by Moore, M. A. S.

Limited Proliferation and Telomere Dysfunction following Telomerase Inhibition in Immortal Murine Fibroblasts¹

James Ewing Laboratory of Developmental Hematopoiesis [J. B., K. L. M., M. A. S. M.], Department of Pediatrics [J. B.], Cell Biology Program, Department of Medicine [G. N.], and Department of Human Genetics [C. M., M. S.], Memorial Sloan-Kettering Cancer Center, New York, New York 10021

Telomerase is a ribonucleoprotein enzyme that functions to maintain telomeres, the terminal DNA that protects chromosomal integrity, regulating cellular replicative life span. Telomerase is not expressed in most normal human somatic cells but is active in stabilizing telomeres of certain self-renewing cell populations and most malignant cells, making the enzyme an appealing target for anticancer therapy. We describe here a novel cross-species approach to telomerase inhibition. Ectopic expression of the human telomerase catalytic reverse transcriptase component in murine cells inhibited endogenous murine telomerase activity. Using this approach, telomerase inhibition in immortal murine fibroblasts resulted in critical telomere shortening, leading to slowed proliferation, abnormal morphology, altered cell cycle, and telomere dysfunction with cytogenetic instability, followed by apoptotic cell death. Subpopulations of two telomerase-inhibited clones escaped widespread apoptosis, showing proliferative recovery in culture despite persistently inhibited telomerase activity with progressive telomere shortening and dysfunction. This study, by targeting immortal murine cells for telomerase inhibition, demonstrates the importance of telomerase to murine cell immortalization and telomere maintenance. Moreover, the murine model used here should prove useful in further evaluating telomerase inhibition as an anticancer therapy.

This article has been cited by other articles:

				Y. Ogawa, M. S. Razzaque, K. Kameyama, G. Hasegawa, S. Shimmura, M. Kawai, S. Okamoto, Y. Ikeda, K. Tsubota, Y. Kawakami, et al. Role of Heat Shock Protein 47, a Collagen-Binding Chaperone, in Lacrimal Gland Pathology in Patients with cGVHD Invest. Ophthalmol. Vis. Sci., March 1, 2007; 48(3): 1079 - 1086. [Abstract] [Full Text] [PDF]

				J. Dupont, J.-B. Latouche, C. Ma, and M. Sadelain Artificial Antigen-Presenting Cells Transduced with Telomerase Efficiently Expand Epitope-Specific, Human Leukocyte Antigen-Restricted Cytotoxic T Cells Cancer Res., June 15, 2005; 65(12): 5417 - 5427. [Abstract] [Full Text] [PDF]

				H. J. Kang, Y. S. Choi, S.-B. Hong, K.-W. Kim, R.-S. Woo, S. J. Won, E. J. Kim, H. K. Jeon, S.-Y. Jo, T. K. Kim, et al. Ectopic Expression of the Catalytic Subunit of Telomerase Protects against Brain Injury Resulting from Ischemia and NMDA-Induced Neurotoxicity J. Neurosci., February 11, 2004; 24(6): 1280 - 1287. [Abstract] [Full Text] [PDF]

				E. S. Wang, K. Wu, A. C. Chin, S. Chen-Kiang, K. Pongracz, S. Gryaznov, and M. A. S. Moore Telomerase inhibition with an oligonucleotide telomerase template antagonist: in vitro and in vivo studies in multiple myeloma and lymphoma Blood, January 1, 2004; 103(1): 258 - 266. [Abstract] [Full Text] [PDF]

				K.-D. Wu, L. M. Orme, J. Shaughnessy Jr, J. Jacobson, B. Barlogie, and M. A. S. Moore Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status, and overall survival Blood, June 15, 2003; 101(12): 4982 - 4989. [Abstract] [Full Text] [PDF]

				S. Chang, C. M. Khoo, M. L. Naylor, R. S. Maser, and R. A. DePinho Telomere-based crisis: functional differences between telomerase activation and ALT in tumor progression Genes & Dev., January 1, 2003; 17(1): 88 - 100. [Abstract] [Full Text] [PDF]